All In Biotech

Drug Trial Radar · NCT05325866

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (FORTITUDE-301)

Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

260

Actual

Start

Sep 23, 2022

Primary completion

Jan 28, 2026

Study completion Jan 28, 2026

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Apr 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.

Conditions

  • Solid Tumors

Interventions

  • BemarituzumabDrug

    Intravenous (IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants Who Experience a Dose Limiting Toxicity (DLT)Time frame: Day 1 to Day 28
  2. Part 1: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)Time frame: Day 1 to 28 days after last dose (a maximum of 2 years)
  3. Part 1: Number of Participants Who Experience a Treatment-related Adverse EventTime frame: Day 1 to 28 days after last dose (a maximum of 2 years)
  4. Part 2: Objective Response (OR) RateTime frame: Up to approximately 2 years

Locations

115 sites in 26 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California

  • University of California Irvine

    Orange, California

  • Rocky Mountain Cancer Centers

    Aurora, Colorado

  • Community Health Network MD Anderson Cancer Center - North

    Indianapolis, Indiana

  • Henry Ford Hospital

    Detroit, Michigan

  • United States Oncology Regulatory Affairs Corporate Office

    Nashville, Tennessee

  • Texas Oncology - Dallas Fort Worth

    Dallas, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • US Oncology Research Investigational Products Center

    Irving, Texas

  • Texas Oncology Northeast Texas

    Tyler, Texas

  • Centro Oncologico Korben

    Buenos Aires, Argentina

  • Instituto Alexander Fleming

    Capital Federal, Buenos Aires, Argentina

  • Hospital Aleman

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Fundacion Cenit Para La Investigacion

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Hospital Italiano de La Plata

    La Plata, Buenos Aires, Argentina

  • Sociedad de Beneficencia Hospital Italiano

    Córdoba, Córdoba Province, Argentina

  • Fundacion Medica de Rio Negro y Neuquen

    Cipolletti, Río Negro Province, Argentina

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

  • Prince of Wales Hospital

    Randwick, New South Wales, Australia

  • Wollongong Hospital

    Wollongong, New South Wales, Australia

  • Toowoomba Hospital

    Toowoomba, Queensland, Australia

  • Cabrini Hospital

    Malvern, Victoria, Australia

  • St John of God Murdoch Hospital

    Murdoch, Western Australia, Australia

  • Medizinische Universitaet Graz

    Graz, Austria

  • Landeskrankenhaus Salzburg

    Salzburg, Austria

  • Universite Catholique de Louvain Cliniques Universitaires Saint Luc

    Brussels, Belgium

  • Grand Hopital de Charleroi - Site des Viviers

    Charleroi, Belgium

  • Universitair Ziekenhuis Antwerpen

    Edegem, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Universitair Ziekenhuis Leuven - Campus Gasthuisberg

    Leuven, Belgium

  • Oncoclinicas Rio de Janeiro S A

    Rio de Janeiro, Brazil

  • Hospital das Clinicas da Ufmg

    Belo Horizonte, Minas Gerais, Brazil

  • Centro de Oncologia Mackenzie

    Curitiba, Paraná, Brazil

  • Associacao Hospitalar Moinhos de Vento

    Porto Alegre, Rio Grande do Sul, Brazil

  • Instituto do Cancer Arnaldo Vieira de Carvalho

    São Paulo, São Paulo, Brazil

  • Beneficencia Portuguesa de Sao Paulo - Bp

    São Paulo, São Paulo, Brazil

  • Oncologia Rede D Or

    São Paulo, São Paulo, Brazil

  • Multiprofile Hospital for Active Treatment Central Onco Hospital OOD

    Plovdiv, Bulgaria

  • Complex Oncology Center Plovdiv EOOD

    Plovdiv, Bulgaria

  • Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia

    Sofia, Bulgaria

Showing 40 of 115 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.